Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 14/20 | 0.36 |
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830957 | 0.80 | MMP9 (0.42) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11484270 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL1404438 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL6079454 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL11598874 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL27738063 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL6691265 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL9190800 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 | |
| SCHEMBL13899710 | 0.71 | — | — | |
| SCHEMBL11677504 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1ALDH1A1ADAMTS5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885NPSR1 4540/4885ALDH1A1 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.